The patient with hormone-refractory prostate cancer: Determining who, when, and how to treat

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 134-140

  Kent, Elizabeth C ^a   Hussain, Maha H A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DIETHYLSTILBESTROL; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; TUMOR PROTEIN;

CANCER GROWTH; CANCER RESEARCH; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; METASTASIS; MORBIDITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SOCIAL SUPPORT; ADENOCARCINOMA; BLOOD; CANCER STEM CELL; CASE MANAGEMENT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; SALVAGE THERAPY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; CASE MANAGEMENT; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MEDICAL FUTILITY; NEOPLASM PROTEINS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TUMOR STEM CELLS;

EID: 1842829888     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.09.005     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 163: 1632-1642, 2000.
3. Arnold JT, and Issacs JT: Mechanisms involved in the progression of androgen-independent prostate cancer: it is not only the cancer cell's fault. Endocr Relat Cancer 9: 61-73, 2002.
4. Bichel P, Fredericksen P, Kjaer T, et al: Flow inicrofluorometry and transrectal dine needle biopsy in the classification of human prostatic carcinoma. Cancer 40: 1206-1211, 1977.
5. Ronstrom L, Tribukait B, and Esposti PL: DNA pattern and cytological findings in fine-needle aspirates of untreated prostatic tumors: a flow-cytofluorometric study. Prostate 2: 79-88, 1981.
6. Van Leenders G, Aalders T, Hulsbergen van de Kaa C, et al: Expression of basal keratins in human prostate cancer metastases and cell lines. J Pathol 195: 563-570, 2001.
7. De Mulder PH, Schalken JA, and Sternberg CN: Treatment options in hormone resistant prostate cancer. Ann Oncol 13(suppl 4): 95-102, 2002.
8. Koivisto P, Kononen J, Palmberg C, et al: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319, 1997.
9. Montgomery JS, Price DK, and Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146, 2001.
10. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
11. Furuya Y, Krajewski S, Epstein JI, et al: Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 2: 389-398, 1996.
12. Kolar Z, Murray PG, Scott K, et al: Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 53: 15-18, 2000.
13. Granchi S, Brocchi S, Bonaccorsi L, et al: Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49: 267-277, 2001.
14. Vicentini C, Festuccia C, Gravina GL, et al: Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 129: 165-174, 2003.
15. Nazareth LV, and Weigel NL: Activation of human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271: 19900-19907, 1996.
16. Cunha GR, Hayward SW, and Wang YZ: Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485, 2002.
17. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467, 1999.
18. Figg WD, Ammermann K, Patronas N, et al: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14: 513-517, 1996.
19. Sridhara R, Eisenberger M, Sinibaldi V, et al: Evaluation of prostate specific antigen (PSA) as a surrogate marker for response of hormone refractory prostate cancer (HRPC) to suramin therapy. J Clin Oncol 13: 2944-2953, 1995.
20. Bauer KS, Figg WD, Hamilton JM, et al: A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res 5: 2324-2329, 1999.
21. Smith DC, Dunn RL, Strawdermann MS, et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843, 1998.
22. Dawson N, Halabi S, Hars V, et al: Prostate-specific antigen (PSA) decline as a predictor of survival: Cancer and Leukemia Group B (CALGB) 9181. Proceedings of the American Society of Clinical Oncology 18: 1209a, 1999. Abstract 1209.
23. Scher HI, Kelly WK, Zhang ZF, et al: Post-therapy prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91: 244-251, 1999.
24. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615, 1993.
25. Kasimis BK, Hwang SS, Chang VT, et al: Survival predictors in stage D2 and D3 prostate cancer (PC): the role of PSA time to nadir (PSA TTN) and PSA doubling time (PSA DT). Proceedings of the American Society of Clinical Oncology 21: 792a, 2002. Abstract 792.
26. Eisenberger M, Crawford ED, McLeod D, et al: The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. Proceedings of the American Society of Clinical Oncology 14: 613a, 1995. Abstract 613.
27. Tannock IF, Osoba S, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14: 1756-1764, 1996.
28. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17: 2506-2513, 1999.
29. Raghavan D, Pearson B, Coorey G, et al: Management of hormone-resistant prostate cancer: experience at Royal Prince Alfred Hospital, in Johnson DE, Logothetis CJ, von Eschenbach AC (Eds): Systemic Therapy for Genitourinary Cancers. Chicago and London, Year Book Medical Publishers. 1989, pp pp 245-250.
30. Fields S, Burris H, Wilding G, et al: Evaluating the role of navelbine in hormone-refractory prostate cancer: a clinical benefit model [abstract]. Proc Am Soc Clin Oncol 13: 727a, 1994.
31. Hudes G, Einhorn L, Ross E, et al: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160-3166, 1999.
32. Small EJ, Baron AD, Fippin L, et al: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157: 1204-1207, 1997.
33. Saica T, Kusaka N, Tsushima T, et al: Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Int J Urol 8: 290-294, 2001.
34. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-597, 1989.
35. Malkowicz SB: The role of diethylstilbestrol in the treatment of prostate cancer. Urology 58(suppl 1): 108-113, 2001.
36. Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86: 222-227, 1994.
37. Schellhammer PF, Venner P, Haas GP, et al: Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157: 1731-1735, 1997.
38. Berry WR, Laszlo J, Cox E, et al: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763-775, 1979.
39. Emrich LJ, Priore RL, Murphy GP, et al: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45: 5173-5179, 1985.
40. McDermott RS, Ross E, Haas N, et al: A prognostic model for survival in androgen independent prostate cancer. Proceedings of the American Society of Clinical Oncology 22: 1610a, 2003. Abstract 1610.
41. Tangen C, Crawford ED, Faulkner J, et al: Ten-year survival in patients with metastatic (M+) prostate cancer (CaP): analysis of Southwest Oncology Group (SWOG) 8894. Proceedings of the American Society of Clinical Oncology 21: 749a, 2002. Abstract 749.
42. Sabbatini P, Larson SM, Kremer A, et al: Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948-957, 1999.
43. DeWys WD, Begg CB, Brodovsky H, et al: A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostate cancer: prognostic factors and response. Prostate 4: 1-11, 1983.
44. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21: 1232-1237, 2003.
45. Smaletz O, Scher H, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972-3982, 2002.
46. Berry W, Dakhil S, Modiano M, et al: Phase III study of mitoxantrone plus low-dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone-refractory prostate cancer. J Urol 168: 2439-2443, 2002.
47. Saad F, Gleason DM, Murray R, et al: A randomized placebo-controlled trial of zoledronic acid in metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2002.
48. Hussain M, Wolf M, Marshall E, et al: Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12: 2005-2012, 1994.
49. Taylor CD, Elson P, and Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11: 2167-2172, 1993.
50. Fowler JE Jr, and Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126: 372-375, 1981.